As of close of business last night, Regenxbio Inc’s stock clocked out at $24.00, down -2.48% from its previous closing price of $24.61. In other words, the price has decreased by -$0.61 from its previous closing price. On the day, 1171169 shares were traded.
Ratios:
To gain a deeper understanding of RGNX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.57 and its Current Ratio is at 2.57. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.26.
On November 01, 2023, Stifel started tracking the stock assigning a Buy rating and target price of $35.Stifel initiated its Buy rating on November 01, 2023, with a $35 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 14 ’24 when Mills Kenneth T. sold 15,000 shares for $16.76 per share. The transaction valued at 251,349 led to the insider holds 408,035 shares of the business.
Mills Kenneth T. sold 45,000 shares of RGNX for $682,992 on Jan 16 ’24. The President and CEO now owns 408,035 shares after completing the transaction at $15.18 per share. On Jan 03 ’24, another insider, PAKOLA STEVE, who serves as the Chief Medical Officer of the company, sold 17,237 shares for $17.39 each. As a result, the insider received 299,789 and left with 107,192 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGNX now has a Market Capitalization of 1.09B and an Enterprise Value of 907.39M. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.82 while its Price-to-Book (P/B) ratio in mrq is 3.39. Its current Enterprise Value per Revenue stands at 10.06 whereas that against EBITDA is -3.79.
Stock Price History:
Over the past 52 weeks, RGNX has reached a high of $28.80, while it has fallen to a 52-week low of $11.83. The 50-Day Moving Average of the stock is 16.35, while the 200-Day Moving Average is calculated to be 17.71.
Shares Statistics:
It appears that RGNX traded 715.34K shares on average per day over the past three months and 1.08M shares per day over the past ten days. A total of 44.05M shares are outstanding, with a floating share count of 39.79M. Insiders hold about 10.44% of the company’s shares, while institutions hold 87.28% stake in the company. Shares short for RGNX as of Feb 15, 2024 were 4.17M with a Short Ratio of 5.84, compared to 4.41M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.48% and a Short% of Float of 12.25%.
Earnings Estimates
As of right now, 8 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$1.23 for the current quarter, with a high estimate of -$0.99 and a low estimate of -$1.4, while EPS last year was -$1.53. The consensus estimate for the next quarter is -$1.2, with high estimates of -$0.99 and low estimates of -$1.47.
Analysts are recommending an EPS of between -$1.41 and -$5.7 for the fiscal current year, implying an average EPS of -$4.34. EPS for the following year is -$2.06, with 9 analysts recommending between $0.53 and -$4.95.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $25.43M. It ranges from a high estimate of $44.5M to a low estimate of $16.69M. As of the current estimate, Regenxbio Inc’s year-ago sales were $19.14M, an estimated increase of 32.90% from the year-ago figure.
A total of 10 analysts have provided revenue estimates for RGNX’s current fiscal year. The highest revenue estimate was $284.76M, while the lowest revenue estimate was $90M, resulting in an average revenue estimate of $147.44M. In the same quarter a year ago, actual revenue was $90.24M, up 63.40% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $239.73M in the next fiscal year. The high estimate is $371.11M and the low estimate is $117.61M. The average revenue growth estimate for next year is up 62.60% from the average revenue estimate for this year.
